Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 185-192

  Irisa, Kaoru ^a   Masago, Katsuhiro ^b   Togashi, Yosuke ^b   Fujita, Shiro ^c   Hatachi, Yukimasa ^b   Fukuhara, Akiko ^b   Sakamori, Yuichi ^b   Kim, Yung Hak ^b   Mio, Tadashi ^b   Mishima, Michiaki ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Charlson comorbidity index; Comorbidity; Elderly; Non small cell lung cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMORBIDITY; FEMALE; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALIDITY; PREMEDICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; ENZYME INHIBITORS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84864028041     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9764-0     Document Type: Article

References (27)

1. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33:2313-4. (Pubitemid 28129168)
2. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570-7.
3. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66-72.
4. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter italian lung cancer in the elderly study (miles) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72. (Pubitemid 36395256)
5. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Phase iii study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the west japan thoracic oncology group trial (WGTOG 9904). J Clin Oncol. 2006;24:3657-63. (Pubitemid 46630541)
6. Firat S, Byhardt RW, Gore E. The effects of comorbidity and age on rtog study enrollment in stage iii non-small cell lung cancer patients who are eligible for rtog studies. Int J Radiat Oncol Biol Phys. 2010;78:1394-9.
7. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Janne PA. Phase ii clinical trial of chemotherapy-naive patients C 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760-6. (Pubitemid 350002874)
8. Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M. Gefitinib versus vinorel-bine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (invite): a randomized, phase ii study. J Clin Oncol. 2008;26:4253-60.
9. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly.: An analysis of the national cancer institute of canada clinical trials group study br.21. J Clin Oncol. 2008;26:2350-7.
10. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol. 2008;26:60-5.
11. Firat S, Byhardt RW, Gore E. Comorbidity and karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four rtog studies. Radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2002;54:357-64. (Pubitemid 35286798)
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-83. (Pubitemid 17055592)
13. Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Da-ures JP, Pujol JL. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: Description and comparison with the charlson's index. Br J Cancer. 2005;93: 1098-105. (Pubitemid 41670692)
14. Li J, Chen P, Dai CH, Li XQ, Bao QL. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. Oncology. 2009;76:355-62.
15. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147-51. (Pubitemid 32176292)
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
17. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, Har-El G, Lucente FE. Validation of the charlson comor-bidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997;107:1469-75. (Pubitemid 27481468)
18. Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, Har-El G, Lucente FE. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998;20:1-7.
19. Lubke T, Monig SP, Schneider PM, Holscher AH, Bollschweiler E. Does charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer? Zentralbl Chir. 2003;128: 970-6. (Pubitemid 37489929)
20. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169:105-9. (Pubitemid 35461563)
21. Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;169:1282-6. (Pubitemid 36323767)
22. Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP. Comparison of the american society of anesthesiologists physical status classification with the charlson score as predictors of survival after radical prostatectomy. Urology. 2003;62: 698-701. (Pubitemid 37205008)
23. Ather MH, Nazim SM. Impact of charlson's comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma. Int Urol Nephrol. 2009;42:299-303.
24. Birim O, Zuydendorp HM, Maat AP, Kappetein AP, Eijkemans MJ, Bogers AJ. Lung resection for non-small-cell lung cancer in patients older than 70: mortality, morbidity, and late survival compared with the general population. Ann Thorac Surg. 2003; 76:1796-801. (Pubitemid 37510479)
25. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-7. (Pubitemid 28175784)
26. Feliu J, Lopez Gomez L, Madronal C, Espinosa E, Espinosa J, Giron CG, Martinez B, Castro J, De la Gandara I, Baron MG. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz cooperative group. Cancer. 1999;86:1463-9. (Pubitemid 29489779)
27. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolo M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D'Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D'Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter italian lung cancer in the elderly study. J Clin Oncol. 2005;23:6865-72.